Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain

José A. G. Agúndez1,2*, Francisco Abad-Santos3, Ana Aldea4, Hortensia Alonso-Navarro5,6, Maria L. Bernal7, Alberto M. Borobia8, Emma Borrás9,10, Miguel Carballo2,9, Alfonso Carvajal10, José D. García-Muñiz1, Guillermo Gervasini1, Félix J. Jiménez-Jiménez5,6, María I. Lucena12,13, Carmen Martínez2,14, Jose A. Sacristán15, Inés Salado16, Blanca Sinues17, Jorge Vicente18 and Elena García-Martín12,19

1 Department of Pharmacology, University of Extremadura, Cáceres, Spain
2 Instituto de Salud Carlos III Spanish Research Network of Adverse Reactions to Allergens and Drugs, Madrid, Spain
3 Servicio de Farmacología Clínica, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain
4 Unidad de Ensayos Clínicos, Hospital Universitario de Canarias, La Laguna, Spain
5 Department of Medicine-Neurology, Hospital Príncipe de Asturias, Alcalá de Henares, Spain
6 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Spain
7 Department of Pharmacology, University of Zaragoza, Zaragoza, Spain
8 Unidad de Farmacogenética Clínica, Servicio de Farmacología Clínica, Hospital Universitario La Paz de Madrid, Instituto de Investigación Hospitalaria Universitaria La Paz, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain
9 Unitat de Genètica Molecular, Hospital de Terrassa, Terrassa, Spain
10 Department of Pharmacology, University of Valladolid, Valladolid, Spain
11 Hospital Universitario de Ceuta, Ceuta, Spain
12 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
13 Departamento Médico, Lilly S.A., Alcobendas, Madrid, Spain
14 Department of Pharmacology, University of Extremadura, Badajoz, Spain
15 Departamento Médico, Lilly S.A., Alcobendas, Madrid, Spain
16 Centro de Estudios sobre la Seguridad de los Medicamentos, Universidad de Valladolid, Valladolid, Spain
17 Instituto de Salud Carlos III Spanish Research Network of Adverse Reactions to Allergens and Drugs, Madrid, Spain
18 Department of Biochemistry and Molecular Biology, University of Extremadura, Cáceres, Spain
19 Department of Pharmacology, University of Extremadura, Cáceres, Spain

*Correspondence: José A. G. Agúndez, Department of Pharmacology, University of Extremadura, Avenida de la Estremera, Avda de la Universidad s/n, E-10071 Cáceres, Spain.
e-mail: jogundez@unex.es

Edited by: Kathryn Kien, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany
Reviewed by: Reinhold Kors, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany
Jose Luis Abel Quiñones, University of Chile, Chile

The development of clinical practice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance with regard to adverse drug reactions. The potential of pharmacogenomic biomarkers has been extensively investigated in recent years. However, several barriers to implementing the use of pharmacogenomics testing exist. We conducted a survey among members of the Spanish Societies of Pharmacology and Clinical Pharmacology to obtain information about the perception of such barriers and to compare the perceptions of participants about the relative importance of major gene/drug pairs. Of 11 potential barriers, the highest importance was attributed to lack of institutional support for pharmacogenomics testing, and to the issues related to the lack of guidelines. Of the proposed gene/drug pairs the highest importance was assigned to HLA-B/abacavir, UGT1A1/irinotecan, and CYP2D6/tamoxifen. In this perspective article, we compare the relative importance of 29 gene/drug pairs in the Spanish study with that of the same pairs in the American Society for Clinical Pharmacology and Therapeutics study, and we provide suggestions and areas of focus to develop a guide for clinical practice in pharmacogenomics testing.

Keywords: biomarkers, adverse drug reactions, pharmacogenomics, clinical recommendations, clinical relevance

Functional polymorphisms of drug-metabolizing enzymes are a major factor involved in adverse drug reactions. The development of pharmacogenomic biomarkers has evolved in recent years, mainly in a frame where these biomarkers are intended to be used as outcome biomarkers, that is, to substitute for a clinical outcome or predict an outcome of a disease or toxicity following treatment. While the most conservative pharmacogenomics views aim to stratify patient populations (patient selection biomarkers) into those who should or should not receive a given drug (Green and Guyer, 2011), other guidelines are intended to adjust drug dose based on pharmacogenomics tests (see for instance Swen et al., 2011). The limitations of pharmacogenomics-based dose adjustment are analyzed elsewhere (Agúndez et al., 2012) and will not be discussed here, but it should emphasized that part of the disenchantment experienced with pharmacogenomics in recent years is related to the overoptimistic expectation of making a safe and reliable personalized dose adjustment based on pharmacogenomics tests. Today we know that interindividual variability in drug metabolism and response exists, even within individuals with identical pharmacogenomics genotypes, and so...
pharmacogenomics is simply another factor to be considered in dose adjustment.

But in even the most conservative approaches to pharmacogenomics (whether individuals would respond to a determined drug, or what patient’s odds are to experience adverse effects with a determined drug), many factors hamper rapid development of the clinical use of pharmacogenomics tests. These factors have been analyzed in detail elsewhere (Deverka et al., 2007; Haga and Burke, 2008; Agúndez, 2009; Agúndez et al., 2009, 2012; Relling et al., 2010; Mathias et al., 2011; Relling and Klein, 2011), but the relative importance of these factors has received little attention. In the frame of the Carlos III Institute of Health (ISCIII) Spanish Research Network of Adverse Reactions to Allergens and Drugs, we conducted a survey in 2012 among members of the Spanish Societies of Pharmacology and Clinical Pharmacology, together with other Spanish clinicians and geneticists closely related to pharmacogenomics, on the most important challenges to clinical implementation of pharmacogenomic tests. The profile of the participants was as follows: 59% were practicing physicians, 21% had an academic research profile, 16% were clinical laboratory professionals, and 3% worked in the pharmaceutical industry. The survey in Spain was designed to include the same gene/drug pairs and the same evaluation criteria as in a US survey (Relling and Klein, 2011) to obtain results which could be directly compared. In addition, we included a survey regarding potential barriers to implementing the use of pharmacogenomics testing (Agúndez et al., 2012). The responses were closed, ranking from 1 to 10 for every item. The ranks obtained for gene/drug pairs were re-scaled in a scale from 1 to 5 to make results comparable to those from the US survey (Relling and Klein, 2011).

Figure 1 summarizes the results, which indicated three major groups of barriers. The most relevant group was related to low institutional promotion, and the second corresponded to lack of clinical guidelines, protocols, and other factors related to validity of pharmacogenetics tests. The barriers in this second group are closely related to one another and, in our opinion, are a major cause of lack of promotion and support for healthcare systems. A third group of barriers with less perceived importance in the survey was related to economical and institutional issues, knowledge of the pharmacogenomic background of the Spanish population and ethical, legal, or social implications.

Because most of the main barriers were related to lack of clinical guidelines and protocols, we included in our survey the same 29 gene/drug pairings listed in a previous study carried out among members of the Clinical Pharmacogenomics Implementation Consortium (CPIC; see http://www.pharmgkb.org/page/cpic) and members of the American Society for Clinical Pharmacology and Therapeutics (Relling and Klein, 2011). The highest ranked pairs (based on the perceived importance of the data linking the drug to the gene variation) were HLA-B/abacavir, UGT1A1/irinotecan, and CYP2D6/tamoxifen (Figure 2). While most gene/drugs pairs received a similar rank in both studies, the comparison revealed that in the Spanish study the gene pairs CYP2C9/celecoxib and CYP2D6/nortriptyline had higher ranks than in the US study, whereas the pairs CYP2C19/aspirin, GPIb/Abciximab, and both genes related to warfarin were ranked lower. Nevertheless, looking at the whole picture, the ranks are similar for most gene/drug pairs, thus indicating that guidelines for gene/drug pairs such as those which are currently being elaborated by CPIC members seem to be well suited for Spain, and probably for other European countries with a similar genetic background. The few discrepancies observed in Figure 2 may be related to the differences in the pattern of drug use in the US and in Spain. CPIC guidelines on some of the gene/drug pairs mentioned have already been published (see for instance Johnson et al., 2011; Crews et al., 2012; Wilke et al., 2012) and many others are currently underway (see http://www.pharmgkb.org/page/cpicGeneDrugPairs). Hopefully
we will soon have guidelines available for all relevant gene/drug pairs.

Nevertheless, some remaining questions related to interethnic and intraspecific genetic variability (García-Martín et al., 2006; García-Martín, 2008; Borobia et al., 2009; Restrepo et al., 2011), refinement in phenotype inference (Agúndez et al., 2008; Ruiz et al., 2012), and detailed studies on the contribution of additional factors which may modify the strength of the association of gene/drugs pairs need to be dealt with. These studies should include gene expression and regulation, patient’s metabolic profile with a given drug, and relevant lifestyle and environmental factors that influence drug metabolism or drug response. Once guidelines and protocols are ready, the major groups of barriers shown in Figure 1 will be weakened. And, in consequence, this
will hopefully lessen the impact of the first and most determinant barrier, since we believe that institutional support and promotion for the use of pharmacogenomics biomarkers will greatly improve as the influence of the other barriers decline.

ACKNOWLEDGMENTS
We are grateful to the coordinators of the Spanish Societies of Pharmacology and Clinical Pharmacology for distributing the survey information and links to all members of the corresponding Union.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 20 September 2012, accepted: 12 November 2012, published online: 26 November 2012.

This article was submitted to Frontiers in Pharmacogenetics and Pharmacogenomics, a specialty of Frontiers in Genetics.

Copyright © 2012 Agúndez, Abad-Santos, Aldea, Alonso-Navarro, Bernal, Benain, Benito, Borrás, Carballo, Carvajal, García-Muñiz, Gaviria, Laguna, Martín. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

REFERENCES
Agúndez, J. A. (2009). Recent advances in drug intolerance. Curr. Drug Metab. 10, 96.
Agúndez, J. A., Del Barrio, J., Padro, T., Stephens, C., Foraz, M., Andrada, R. L., et al. (2012). Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the Spanish Society of Clinical Pharmacology. Front. Pharmacol. 3.2. doi: 10.3389/fphar.2012.00002
Agúndez, J. A., Garcia-Martín, E., and Martínez, C. (2009). Genetically based impairment in CYP2C9 and CYP2C9-dependent N-acetyl metabolism as a risk factor for gastrointestinal bleeding is a combination of pharmacogenetics and metabolomics required to improve personalized medicine. Expert Opin. Drug Metab. Toxicol. 5, 607–628.
Agúndez, J. A., Góka, R., Martínez, C., Slavinski, S., Blaukovich, M., and Garcia-Martín, E. (2008). Uncovering ambiguous NAT2 genotyping data. Clin. Chem. 54, 1390–1394.
Borobia, A. M., Lopez-Pardo, A. M., Taboas, R., Ramirez, E., Barea, C., Arroyo-Pardo, E., et al. (2009). CYP2C9 polymorphism in five autochthonous population of the same geographic area (Spanish Pyrenees). Pharmacogen. Res. 29, 107–111.
Crow, K. R., Gaudigi, A., Duman-Ross, H. M., Klein, T. E., Shu, D. Y., and Elghanian, T. E. (2011). A clinical Pharmacogenetics Implementation Consortium (CPCi) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol. Ther 91, 321–326.
De vries, P. A., Dokiyan, T., and Carlson, B. R. (2007). Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges. Clin. Pharmacol. Ther 83, 427–434.
García-Martín, E. (2008). Interspecific and intraspecific variability of NAT2 single nucleotide polymorphisms. Curr. Drug Metab. 9, 487–497.
García-Martín, E., Martínez, C., Ladens, J. M., and Agúndez, J. A. (2008). Interspecific and intraspecific variability of CYP2C9 and CYP2C9 polymorphisms in healthy individuals. Mutat. Res. Drugs Ther. 107, 29–40.
Green, E. D., andGuyer, M. S. (2011). Pharmacogenetics: from bench to bedside. Nature Medicine from base pairs to bedside. Nature 470, 204–213.
Hajj, S. B., and Burke, W. (2008). Pharmacogenetic testing: not as simple as it seems. Genet. Med. 10, 391–395.
Johnson, J. A., Gong, L., Whel-Chiarmi, M., Gage, B. F., Scott, S. A., Stein, C. M., et al. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2D6 and CYP2C19 genotypes and warfarin dosing. Clin Pharmacol Ther 90, 625–639.
Mathis, K., Laurie, D., Andramouz, C., Abet, N., Badimou, L., Bramer, T., et al. (2011). A gene-based and operational strategy to quality transplant safety biomarkers. Drug Disc. Today 16, 500–608.
Rolling, M. V., Altman, R. B., Goetz, M. P., and Franx, W. E. (2010). Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11, 507–509.
Rolling, M. V., and Klein, T. E. (2011). CPCi Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther 89, 464–467.
Rustepo, J. G., Martinez, C., Garcia-Martin, E., Gurri, B., et al. (2011). Cyp2C9 P490 CYP2D6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2D6 alleles. Pharmacogenet. Genom. 21, 773–778.
Rutten, J. D., Martinez, C., Anderson, K., Gross, M., Lang, N. P., Garcia-Martin, E., et al. (2012). The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PLoS ONE 7, e44629. doi: 10.1371/journal.pone.0044629
Swen, J. E., Njehouh, M., De Bon, A., Guenka, L., Marland-Van Der Zee, A. H., Malde, H., et al. (2011). Pharmacogenetics: from bench to bedside – an update of guidelines. Clin Pharmacol Ther 89, 642–673.
Wilke, R. A., Rutgers, I. B., Johnson, S. G., Mannelli, W. D., Milder, H. L., Voora, D., et al. (2012). The Clinical Pharmacogenetics Implementation Consortium: CPCi guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol. Ther 92, 112–117.
